{
}
UBS CEO Sergio Ermotti earned CHF 14.9 million for 2024, a slight increase from CHF 14.4 million in 2023, despite only serving nine months that year. His compensation includes CHF 2.8 million in fixed salary and CHF 12.1 million in variable pay. Meanwhile, a motion in the Council of States seeks to cap bank executives' salaries at CHF 3 to 5 million annually, potentially impacting Ermotti's future earnings.
The Swiss bond market saw yields of 0.35% for two-year bonds and 0.767% for ten-year bonds, with the spot interest rate easing to 0.704%. The euro gained against the US dollar, now above 1.09, amid expectations of a supportive fiscal package in Germany and a busy week for central bank announcements, including the Fed and SNB. US stock markets are anticipated to open lower, influenced by Treasury Secretary Scott Bessent's comments on market corrections, while Nvidia shares rose ahead of a key AI conference.
Serena Fioravanti has been appointed to the Board of Directors of Migros Bank, filling the vacancy left by Ursula La Roche. Currently the Group Chief Risk Officer at ABN Amro, Fioravanti brings extensive experience from her previous roles at Credit Suisse, Novartis, and UBS, along with a background in theoretical physics from the University of Rome. Chairman Bernhard Kobler highlighted her expertise in risk management, treasury, and liquidity management.
The Swiss stock market closed slightly higher, with the SMI rising 0.15% to 12,893.98 points, buoyed by gains in cyclical and financial stocks. Notable performers included OC Oerlikon (+8.7%) and Basilea (+8.3%), while Lonza (-2.7%) and Siegfried (-6.3%) faced declines due to conservative outlooks. Encouraging economic signals from Germany and the USA contributed to a positive market sentiment.
Migros Bank has appointed Serena Fioravanti to its Board of Directors, effective March 1, 2025, filling the vacancy left by Ursula La Roche's departure in mid-2024. Fioravanti, a risk specialist, previously served as Chief Risk Officer at Credit Suisse Switzerland and is currently the Group Chief Risk Officer at ABN Amro.
Novartis AG, which focuses on healthcare products, has 13.12% of its stock owned by institutional investors. The company recently received mixed ratings from analysts, with a consensus rating of "Hold" and a price target of $123.38. Despite beating earnings expectations, Novartis shares have faced downward pressure, reflecting a cautious outlook among investors.
UBS Group experienced a slight decline in share price, dropping 0.22% to EUR 31.95 on February 14, 2025. The bank has been actively managing its portfolio, downgrading Novartis shares from "Buy" to "Neutral" and adjusting the price target, while also raising AppLovin's target significantly. With a market capitalization of 110.6 billion euros, UBS remains a key player in global financial services, prompting shareholders to consider their next moves.
UBS shares have been removed from a model portfolio by a strategist, following a recent reinstatement by another analyst. The Swiss market shows mixed performance, with Givaudan gaining slightly while Sonova and Dätwyler face declines. Notable updates include Galderma receiving EMA marketing authorization and Novartis gaining FDA orphan drug designation for Ianalumab.
Novartis AG is experiencing a "sharp deceleration" in growth projected by mid-2025, according to UBS. The company's sales are primarily driven by oncology (29.3%), immunology (18.5%), and cardiovascular, renal, and metabolic diseases (17%), with contract manufacturing accounting for 25.8%. Geographically, sales are distributed as follows: USA (42%), Europe (30.9%), Asia-Africa-Australasia (20%), and Canada and Latin America (7.1%).
Novartis AG, a leading pharmaceutical company, is projected to experience a significant slowdown in growth by mid-2025. Its sales are primarily derived from oncology (29.3%), immunology (18.5%), and cardiovascular, renal, and metabolic diseases (17%), with a notable 25.8% from contract manufacturing. Geographically, 42% of sales come from the USA, followed by Europe (30.9%) and Asia/Africa/Australasia (20%).
Novartis AG
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs ceo sergio ermotti earns 14.9 million amid salary cap debate
Swiss Franc
Novartis AG
Credit Suisse Strategic Income I
CHE
Sergio Ermotti
Thierry Burkart
Jakob Stark
Vas Narasimhan
Show more
06:52 17.03.2025
global markets brace for central bank decisions amid mixed stock performances
United States Dollar
Euro
Swiss Franc
Novartis AG
Logitech International S.A.
Norwegian Cruise Line Holdings Ltd.
NVIDIA Corporation
Hoffmann-La Roche AG
RICHEMONT, Intellectual Property Services
JPMorgan Chase & Co.
Tesla, Inc.
DEU
USA
CHE
Jensen Huang
Scott Bessent
Donald Trump
Jerome Powell
Benjamin Picton
Vladimir Putin
Thomas Stucki
Show more
05:11 17.03.2025
serena fioravanti joins migros bank board of directors as risk expert
Swiss Franc
Migros Bank (CH) Fds 65 V
ABN AMRO Bank N.V.
Credit Suisse High Yield Bond Fund, Inc.
Novartis AG
CHE
ITA
NLD
Bernhard Kobler
Serena Fioravanti
Ursula La Roche
Show more
08:28 18.02.2025
Swiss stock market edges up as Oerlikon and Basilea report strong results
United States Dollar
Euro
Swiss Franc
Straumann Holding AG
Roche Holding AG
Lonza Group AG
ABB Ltd
Sandoz Group AG
Julius Bär Gruppe AG
Alstom SA
Novartis AG
Swiss Re AG
Nestlé S.A.
Zurich, Agence générale Christian Meier SA
OC Oerlikon Corp AG, Pfaffikon
DEU
USA
CHE
Show more
08:06 18.02.2025
serena fioravanti joins migros bank board of directors effective march 2025
Swiss Franc
ABN AMRO Bank N.V.
Credit Suisse High Yield Bond Fund, Inc.
Migros Bank (CH) Fds 0 I
Novartis AG
CHE
NLD
Serena Fioravanti
Ursula La Roche
Show more
07:24 18.02.2025
novartis stock analysis shows mixed ratings from analysts and institutional investors
14:41 14.02.2025
ubs shares see slight decline as investment strategies shift
11:02 14.02.2025
market updates shares performance and analyst recommendations in europe and us
Vetropack Holding AG
Nestlé S.A.
Sonova R
SGS SA
Novartis AG
Lukas Ruflin
Mensur Pocinci
Rainer-Marc Frey
Show more
08:11 14.02.2025
novartis anticipates significant growth slowdown by mid 2025 according to ubS
18:10 13.02.2025
Novartis anticipates significant growth slowdown by mid 2025
18:03 13.02.2025
Trending
Subcategory
Countries:
Companies:
Currencies:
People: